Mark Ragosa - Mar 16, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: Mar 16, 2023
Transactions value $: -$9,984
Form type: 4
Date filed: 3/20/2023, 05:14 PM
Previous filing: Sep 6, 2022
Next filing: Apr 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+872	+11.37%		8.54K	Mar 16, 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$2.93K	-256	-3%	$11.46	8.29K	Mar 16, 2023	Direct
transaction	KNSA	Class A Common Share	Options Exercise		+2.16K	+26.04%		10.4K	Mar 20, 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$7.05K	-634	-6.07%	$11.12	9.81K	Mar 20, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-872	-33.33%	$0.00	1.74K	Mar 16, 2023	Class A Common Share	872		Direct	F1, F2
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-2.16K	-100%	$0.00^*	0	Mar 20, 2023	Class A Common Share	2.16K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.
F3	The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.